The prevalence of hypertension (HTN) and renal cell carcinoma (RCC) keeps increasing. In
2019, one-third of people between 30 and 70 years old were estimated to have HTN …

Advances in tumor diagnosis and treatment, especially the use of targeted therapies, have
remarkably improved the survival rate of patients with renal cell carcinoma (RCC) …

e16085 Background: Patients with renal cell carcinoma (RCC) often harbor risk factors for
cardiovascular disease and may receive anti-VEGF agents, which are associated with …

Renal cell carcinoma (RCC) accounts for 2%–3% of all adult malignancies, representing the
seventh most common cancer in men and the ninth most common cancer in women [1] …

Highlights• With several newly approved regimens for RCC, cardiovascular risks must be
considered during treatment selection.• Although uncommon, toxicities associated with …

Background/Aim: Hypertension is a risk factor for occurrence of renal cell carcinoma;
however, it remains unclear whether hypertension affects development and prognosis of …

Approximately one-third of patients with RCC3 have metastatic disease at initial
presentation or on relapse, and the prognosis for metastatic RCC remains highly …

In the study “Cardiovascular profile of contemporary treatments of renal cell carcinoma: A
single-center prospective study” by Lee et al. published in IJC [1] the Authors highlight the …

Outstanding progress has been made over the past decade for the treatment of metastatic
renal cell carcinoma (RCC)[1]. Targeted agents, including anti-VEGFs and mTOR inhibitors …

Renal cell carcinoma (RCC) is a malignant tumor and the third most common urinary
disease. It was estimated that RCC affected over 350,000 individuals in 2013, and there are …